MAP6 and schizophrenia: Schizophrenia also presents positive symptoms, and MAP6 KO mice exhibited increased locomotor activity (Andrieux et al., 2002; Brun et al., 2005; Fradley et al., 2005; Bouvrais-Veret et al., 2007) associated with hypersensitivity to novelty or to the psychostimulant amphetamine (Brun et al., 2005; Bégou et al., 2007; Bouvrais-Veret et al., 2008), along with extensive disruption of sleep patterns (Profitt et al., 2016).